SAN DIEGO, Dec. 29, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S.,...
Read Full StoryTop News
Related
US Government buys doses of Eli Lilly’s COVID treatment
wamwamfm.com
, 3min
0

House Covid Relief Bill Extends Unemployment Benefits by 5 Months, Pays Extra $400 a Week
nbcconnecticut.com
, 7min
0

WWII plane flypast marks Capt. Tom Moore's funeral
sandiegouniontribune.com
, 15min
0

New Travis County group aims to supply minority communities with PPE in fight against COVID-19
kxan.com
, 5min
0

Physiological Saline Market Statistics, CAGR, Outlook, and Covid-19 Impact 2021
thedailychronicle.in
, 40min
0

Creighton University students help residents file taxes
ketv.com
, 6min
0

Van ECK Associates Corp Acquires 7,792 Shares of Guardant Health, Inc. (NASDAQ:GH)
modernreaders.com
, 6min
0

A lesson from the storm: remember vulnerable kids
statesman.com
, 6min
0

S and P 500 - 3 Reasons the Stock Market Could Crash in the Next 3 Months
fintechzoom.com
, 7min
0

House passes Biden’s $1.9 Trillion Covid-19 relief package
wlns.com
, 8min
0

TRADITIONAL CUSTOMS OR FESTIVALS
Coast Coliseum sees ticket sales soar as Crawfish Music Festival crawls closer
wlox.com
, 8min
0

Triple-S Management (NYSE:GTS) Shares Gap Down to $25.89
modernreaders.com
, 8min
0

Triple-S Management (NYSE:GTS) Shares Gap Down to $25.89
modernreaders.com
, 8min
0

Triple-S Management (NYSE:GTS) Shares Gap Down to $25.89
modernreaders.com
, 8min
0
